Navigation Links
JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash
Date:3/11/2009

sed or within any particular schedule. Any information regarding Patheon contained herein has been taken from, or is based upon, publicly available information. Although JLL does not have any information that would indicate that any information contained herein is inaccurate or incomplete, JLL does not undertake any responsibility for the accuracy or completeness of such information. JLL does not undertake, and specifically disclaims, any obligation or responsibility to update or amend any of the information above except as otherwise required by law.

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements that involve risks and uncertainties. Often, but not always, forward-looking statements can be identified by the use of words such as "plans," "expects," "expected," "scheduled," "estimates," "intends," "anticipates," or "believes," or variations of such words and phrases, or state that certain actions, events or results "may," "could," "would," "might" or "will" be taken, occur or be achieved. These forward-looking statements reflect JLL's best judgment based on current information, factors and assumptions, and although it bases these statements on circumstances that it believes to be reasonable when made, there can be no assurance that future events will not affect the accuracy of such forward-looking information. As such, the forward-looking statements are not guarantees of future performance or actions, and actual performance and actions may vary materially from the actions and expectations discussed in this documentation. JLL disclaims any intention or obligation to update or revise any forward looking information whether as a result of new information, future events or otherwise, except as required by applicable law.

    The Information Agent for              The Dealer Manager for
     the offer is:                          the offer is:
'/>"/>
SOURCE JLL Patheon Holdings, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Exelixis Commences Public Offering of Common Stock
3. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
4. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
5. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
6. Cytopia Commences Phase II Cancer Drug Study
7. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
8. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
9. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
10. China Sky One Medical, Inc. Commences Trading on the American Stock Exchange
11. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... rats exposed to high-energy particles, simulating conditions astronauts would ... in attention and slower reaction times, even when the ... The cognitive impairments which affected a large subset, ... to be linked to protein changes in the brain, ... true in humans, suggest it may be possible to ...
(Date:4/23/2014)... the gastro-intestinal tract has long been considered to be ... Sahlgrenska Academy have used refined microscopic techniques that indicate ... of the gastro-intestinal tract is only as large as ... The digestive tract, which passes from the mouth through ... length of about 5 meters in a normal adult, ...
(Date:4/23/2014)... The American Gastroenterological Association (AGA) Research Foundation is ... The AGA Research Scholar Awards program, launched in ... productive research careers in digestive diseases. This year, ... year allowing for three consecutive years of funding. ... who are paving the way for promising research ...
(Date:4/23/2014)... SEATTLE, Washington, April 21, 2014 Five for-profit ... total of $1.25 million in Proof of Concept ... from ideas into commercial products, the Life Sciences ... a $300,000 Entrepreneur Mentoring Program grant to the ... a statewide advisory network to train the next ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
Breaking Medicine News(10 mins):Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... to a new study in Clinical Gastroenterology and ... could help physicians know which patients will benefit most ... and Hepatology is the official journal of the ... or cholecystectomies, are performed annually in the U.S. at ...
... taking folic acid supplements during pregnancy reduces the risk ... little is known about the relationship between prenatal folic ... between investigators at the Norwegian Institute of Public Health ... now reported that mothers who took folic acid supplements ...
... , TUESDAY, Oct. 11 (HealthDay News) -- Studies ... injury are plagued by design problems, a new report issued ... upshot: While evidence exists that this kind of therapy helps ... strong enough to develop definitive guidelines for its use. ...
... -- Men who become parents later in life are not ... study suggests. Researchers in Sweden found children born to ... kids with fathers in their 30s. The findings, they noted, ... have a negative impact on his children,s IQ. In ...
... E supplement a regimen once thought to reduce cancer ... to results of a large national study. The finding ... Selenium and,Vitamin E Cancer Prevention Trial (SELECT). Eric Klein, M.D., ... Clinic, is the lead author. SELECT began in 2001 ...
... Oct. 11 (HealthDay News) -- A small, preliminary study finds that ... a potential sign that the pills might reduce the risk of ... and the researchers aren,t yet recommending that people head to the ... "If you want to add ginger to part of a ...
Cached Medicine News:Health News:Pain characteristics suggest higher benefit from gallbladder surgery 2Health News:Folic acid supplements in early pregnancy may reduce the risk of severe language delay in children 2Health News:Evidence Lacking That Cognitive Rehab Therapy Helps Brain-Injured Vets 2Health News:Evidence Lacking That Cognitive Rehab Therapy Helps Brain-Injured Vets 3Health News:National study finds vitamin E supplement may increase prostate cancer risk 2Health News:Ginger Supplements Might Ease Inflammation Linked to Colon Cancer 2
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... NEW YORK, Oct. 25, 2011 Reportlinker.com ... is available in its catalogue: ... Market Forecasts to 2018 ... - Pipeline Assessment and Market Forecasts to ...
... YORK, Oct. 25, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiries ... Aricept, Namenda, Avonex, Rebif and Copaxone ...
Cached Medicine Technology:Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 11Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 2Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 3Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 4Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 5Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 6Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 7Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 8Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 9Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 10Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 11Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 13Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 14Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 15
... Merit has a complete offering of ... Performa brands, these catheters are designed with ... shaft strength and better push-ability, and large ... in 4, 5, 6 and 7 French ...
Used to negotiate tortuous vessels....
Used for vascular and non-vascular applications. Tapered fixed core construction provides gradual transition to a flexible,tip. Supplied sterile in peel-open packages. Intended for one-time use....
Used to negotiate tortuous vessels....
Medicine Products: